TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03743402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management training
Description: This intervention will have 4 components:~1. telephone-delivered evidence-based pain self-management training,~2. web-based video of successfully tapered patients with motivational interviewing debriefing,~3. a voluntary, self-paced opioid taper~4. opioid and non-opioid prescribing guidance for the patient's primary care provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video education, motivational interviewing
Description: web-based video of successfully tapered patients with motivational interviewing debriefing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voluntary self-paced opioid taper
Description: Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prescribing guidance for primary care provider
Description: Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses
Study: NCT01709773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal treatment
Description: Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
Study: NCT01412892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001: Everolimus
Description: 10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
Study: NCT00968188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep It Up!
Description: Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information only
Description: Medically fact based HIV information delivered online.
Study: NCT02706353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
Study: NCT03707366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHF-T
Description: FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
Study: NCT03410901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Antibody BMS 986178
Description: Given IV, intratumoral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR9 Agonist SD-101
Description: Given intratumorally
Study: NCT02805985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLXfit™ TLIF Interbody Fusion Device
Description: The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
Study: NCT03245619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3335065
Description: GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3335065
Description: GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3335065
Description: GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3335065
Description: GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
Study: NCT02183909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing and linkage to care for Y/MSM
Description: Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
Study: NCT03245619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
Study: NCT03401723

Intervention type: OTHER
Group type: OTHER
Intervention: 3D-Colonoscopy Progression Score
Description: 3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.

Intervention type: OTHER
Group type: OTHER
Intervention: 3D-Colonoscopy Progression Score
Description: 3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.

Intervention type: OTHER
Group type: OTHER
Intervention: Endoscopy Training System
Description: The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~1. Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~2. Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~3. Loop Management - The management of a standard alfa-loop.~4. Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal.

Intervention type: OTHER
Group type: OTHER
Intervention: Endoscopy Training System
Description: The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~1. Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~2. Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~3. Loop Management - The management of a standard alfa-loop.~4. Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal.

Intervention type: OTHER
Group type: OTHER
Intervention: 3D-Colonoscopy Retraction Score
Description: 3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.

Intervention type: OTHER
Group type: OTHER
Intervention: 3D-Colonoscopy Retraction Score
Description: 3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
Study: NCT02183909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement and retention for HIV-positive Y/MSM in care
Description: Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Engagement and retention for HIV-negative Y/MSM in sexual health services
Description: Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild PEP Substudy
Description: A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
Study: NCT02554422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PalpEar
Description: Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
Study: NCT04269434

Intervention type: OTHER
Group type: OTHER
Intervention: No Screening
Description: the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
Study: NCT02928471

Intervention type: DIETARY_SUPPLEMENT
Intervention: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study: NCT03694262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib 600mg orally twice daily by continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg IV on day 1 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1,200mg IV on day 1 of every cycle
Study: NCT00429442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 80 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: calcium tablets once daily
Study: NCT04223128

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided transversus abdominis plane block
Description: Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided transversus abdominis plane block
Description: Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided transversus abdominis plane block
Description: Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
Study: NCT01292577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CET/PT
Description: CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
Study: NCT03643913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular block
Description: Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Blocking Agents and reversing agents
Description: Deep neuromuscular block versus moderate neuromuscular block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents and reversing agents
Description: Deep neuromuscular block versus moderate neuromuscular block.
Study: NCT03650296

Intervention type: DEVICE
Intervention: ePER vs PS vs PaedER
Description: see detailed description of methods

Intervention type: DEVICE
Intervention: ePER vs PS vs PaedER
Description: see detailed description of methods

Intervention type: DEVICE
Intervention: ePER vs PS vs PaedER
Description: see detailed description of methods
Study: NCT04826133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 μg (three capsules of 0.5 μg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.
Study: NCT01174810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
Study: NCT01546038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28-days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ARA-C (LDAC)
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin given using 60 mg/m2 for 3-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 100 mg/m2 on days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin given using 60 mg/m2 for 3-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 100 mg/m2 on days 1 through 7

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)

Intervention type: DRUG
Group type: OTHER
Intervention: Low dose ARA-C (LDAC)
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Study: NCT04587401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: normotensive patients
Description: patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients with hypertension diagnosis
Description: Patients who have high blood pressure diagnosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients who do not know they are hypertensive but actual blood pressure is high
Description: patients with preoperative high blood pressure, who do not know they are hypertensive
Study: NCT01511003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study: NCT00231309

Intervention type: DRUG
Group type: OTHER
Intervention: Granulocyte Colony Stimulating Factor
Description: Granulocyte Colony Stimulating Factor
Study: NCT01827878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Study: NCT01411449

Intervention type: DRUG
Intervention: Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Description: Patients who will need to undergo contrast enhanced MRI with Primovist
Study: NCT03919409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules
Study: NCT01531595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus alternating XELOX/XELIRI
Description: 3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
Study: NCT03919409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161
Description: TS-161 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-161 Placebo
Description: TS-161 matching placebo capsules